secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001493152-24-048734
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus grants ~49.5M stock options to CEO, President, CFO, CTO, directors; CFO salary raised to $200K
--------------------------------------------------------------------------------

- CEO Ed Pershing receives 25,470,215 options (grant date value $3,081,896) at $0.2862 exercise price.
- President Dominic Rodrigues receives 16,146,600 options ($1,953,739); CFO Heather Raines receives 4,197,890 options ($507,945).
- CFO base salary increased from $125,000 to $200,000 effective Dec 1, 2024; new employment agreement includes change-in-control provisions.
- Options vest in three equal annual installments for officers; independent directors’ options vest immediately.
- All option grants approved by Board on Nov 18, finalized Dec 2, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224048734/0001493152-24-048734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224048734/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer